Text table 2
Mortality reduction associated with adjuvant treatment, by receptor status, age range, and breast cancer stage Text table 2
Mortality reduction associated with adjuvant treatment, by receptor status, age range, and breast cancer stage

Text table 2
Mortality reduction associated with adjuvant treatment, by receptor status, age range, and breast cancer stage
Table summary
This table displays the results of Mortality reduction associated with adjuvant treatment. The information is grouped by Receptor status (appearing as row headers), Age and Mortality reduction, % (treatment type), calculated using Ductal carcinoma in situ and Invasive cancer, including distant units of measure (appearing as column headers).
Receptor status	Age	Mortality reduction, % (treatment type)
Receptor status	Age	Ductal carcinoma in situ	Invasive cancer, including distant
ER +	Younger than 50 50 or older	32 (tamoxifen) 32 (tamoxifen)	58 (chemotherapy and tamoxifen) 53 (chemotherapy and aromatase inhibitor)
ER -	Younger than 50 50 or older	0 (no adjuvant) 0 (no adjuvant)	38 (chemotherapy) 38 (chemotherapy)
HER2+	All ages	0 (no adjuvant)	33 (herceptin)
ER+/ER- = estrogen receptor positive/estrogen receptor negative HER2 = human epidermal growth factor receptor 2 Source: Early Breast Cancer Trialists’ Collaborative Group (EBCTCG).^{Note 11}

Language selection